Haemonetics believes that fiscal 2013 is likely to be a ground breaking year based on several growth factors, including the acquisition of the transfusion medicine business of Pall Corp. ( PLL) in August 2012, the limited market release of the paperless phlebotomy offering by the end of the fourth quarter of fiscal 2013 and its emerging-market growth initiatives with a primary focus on China.

FORBES: Momentum Players Have Lots To Like About Haemonetics